The correlation between AMH and number of embryos in POSEIDON groups: a retrospective cohort study.

[1]  J. Laven,et al.  DEBATE: AMH as the Primary Marker for Fertility. , 2019, European journal of endocrinology.

[2]  L. Rienzi,et al.  The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists , 2019, Front. Endocrinol..

[3]  P. Humaidan,et al.  Cumulative Live Birth Rates in Low Prognosis Patients According to the POSEIDON Criteria: An Analysis of 26,697 Cycles of in vitro Fertilization/Intracytoplasmic Sperm Injection , 2019, Front. Endocrinol..

[4]  S. Esteves,et al.  Future Perspectives of POSEIDON Stratification for Clinical Practice and Research , 2019, Front. Endocrinol..

[5]  Honglin Liu,et al.  MicroRNAs in ovarian follicular atresia and granulosa cell apoptosis , 2019, Reproductive Biology and Endocrinology.

[6]  S. Esteves,et al.  Novel approaches for diagnosis and management of low prognosis patients in assisted reproductive technology: the POSEIDON concept. , 2019, Panminerva medica.

[7]  Fabiola C. Bento,et al.  Estimation of age-dependent decrease in blastocyst euploidy by next generation sequencing: development of a novel prediction model. , 2019, Panminerva medica.

[8]  H. Tournaye,et al.  Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a multicenter multinational analysis including ∼15,000 women. , 2018, Fertility and sterility.

[9]  C. Gracia,et al.  Multicenter evaluation of the Access AMH antimüllerian hormone assay for the prediction of antral follicle count and poor ovarian response to controlled ovarian stimulation. , 2018, Fertility and sterility.

[10]  G. Patounakis,et al.  Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance , 2018, Human reproduction.

[11]  C. Gracia,et al.  Multi-center clinical evaluation of the Access AMH assay to determine AMH levels in reproductive age women during normal menstrual cycles , 2018, Journal of Assisted Reproduction and Genetics.

[12]  S. Esteves,et al.  Individualized controlled ovarian stimulation in expected poor-responders: an update , 2018, Reproductive Biology and Endocrinology.

[13]  V. Baker,et al.  Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013. , 2018, Fertility and sterility.

[14]  D. Seifer,et al.  Ovarian reserve testing: a user's guide , 2017, American journal of obstetrics and gynecology.

[15]  S. Esteves,et al.  The novel POSEIDON stratification of ‘Low prognosis patients in Assisted Reproductive Technology’ and its proposed marker of successful outcome , 2016, F1000Research.

[16]  F. Ubaldi,et al.  A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. , 2016, Fertility and sterility.

[17]  V. Baker,et al.  Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013. , 2016, Fertility and sterility.

[18]  S. Iliodromiti,et al.  Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response. , 2015, Human reproduction update.

[19]  S. Nelson,et al.  Two new automated, compared with two enzyme-linked immunosorbent, antimüllerian hormone assays. , 2015, Fertility and sterility.

[20]  L. Nardo,et al.  Prospective study into the value of the automated Elecsys antimüllerian hormone assay for the assessment of the ovarian growing follicle pool. , 2015, Fertility and sterility.

[21]  A. Badawy,et al.  Prediction and Diagnosis of Poor Ovarian Response: The Dilemma , 2011, Journal of reproduction & infertility.

[22]  F. Broekmans,et al.  The antral follicle count: practical recommendations for better standardization. , 2010, Fertility and sterility.

[23]  A. Volpe,et al.  Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). , 2010, Human reproduction update.

[24]  M. Eijkemans,et al.  Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. , 2010, Human reproduction.

[25]  T. Yavuz,et al.  Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. , 2007, European journal of obstetrics, gynecology, and reproductive biology.

[26]  A. Volpe,et al.  Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. , 2007, Human reproduction.

[27]  D. Seifer,et al.  Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. , 2002, Fertility and sterility.